SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (242)7/2/2003 7:11:05 PM
From: Miljenko Zuanic  Read Replies (3) of 590
 
ABGX takeover makes much more sense than past MLNM rumor. Two main reasons:

1. Control of the ABX-EGF (they are the only who knows how first line PII are progressing).
2. ABGX manufacturing capacity, IF DNA turned them down with 4x12KL reactors license (which is now very likely).

AMGN will also have in-house mAb generation and validation capacity, which can not be neglected. ABGX licensors will be left behind.

The question is what price ABGX will accept, and what will AMGN offer?

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News